Josep M. Campistol

Director general del Hospital Clínic

Publicacions destacades

  • Fine tuning the extracellular environment accelerates the derivation of kidney organoids from human pluripotent stem cells

    Autors: Garreta E, Prado P, Tarantino C, Oria R, Fanlo L, Martí E, Zalvidea D, Trepat X, Roca-Cusachs P, Gavaldà-Navarro A, Cozzuto L, Campistol JM, Izpisúa Belmonte JC, Hurtado Del Pozo C, Montserrat N .
    Referència: NATURE MATERIALS.
  • Inotersen treatment for patients with Hereditary transthyretin amyloidosis

    Autors: Benson M., Waddington-Cruz M., Berk J., Polydefkis M., Dyck P., Wang A., Planté-Bordeneuve V., Barroso F., Merlini G., Obici L., Scheinberg M., Brannagan T., Litchy W., Whelan C., Drachman B., Adams D., Heitner S., Conceição I., Schmidt H., Vita G., Campistol J., Gamez J., Gorevic P., Gane E., Shah A., Solomon S., Monia B., Hughes S., Jesse Kwoh T., McEvoy B., Jung S., Baker B., Ackermann E., Gertz M., Coelho T..
    Referència: NEW ENGLAND JOURNAL OF MEDICINE.
  • Outcomes From Brain Death Donors With Previous Cardiac Arrest Accepted for Pancreas Transplantation: A Single-center Retrospective Analysis

    Autors: Ventura-Aguiar P, Ferrer J, Paredes D, Rodriguez-Villar C, Ruiz A, Fuster J, Fondevila C, Garcia-Valdecasas JC, Esmatjes E, Adália R, Oppenheimer F, Campistol JM, Diekmann F, Ricart MJ .
    Referència: Annals Of Surgery 2019; ():-.
  • Treatment of Active Chronic Antibody-Mediated Rejection with Rituximab, IVIG and Plasma Exchange.

    Autors: Pineiro, G.; Rovira, J.; De Sousa-Amorim, E.; Villarreal, J.; Sole, M.; Revuelta, I.; Lozano, M.; Palou, E.; Oppenheimer, F.; Campistol, J.; Diekmann, F.;.
    Referència: AMERICAN JOURNAL OF TRANSPLANTATION 2018.
  • Different Expression Patterns of Exosomal miRNAs under Cyclosporin A and Rapamycin Treatment in Distinct Aggressiveness Colorectal Carcinomas.

    Autors: Tubita, V.; Ramirez-Bajo, M.; Lozano, J.; Moya-Rull, D.; Rovira, J.; Campistol, J.; Diekmann, F.; Revuelta, I.;.
    Referència: AMERICAN JOURNAL OF TRANSPLANTATION 2018.
  • Tofacitinib halts progression of graft dysfunction in a rat model of mixed cellular and humoral rejection.

    Autors: Rovira J, Ramírez-Bajo MJ, Banon-Maneus E, Lazo-Rodríguez M, Moya-Rull D, Hierro-Garcia N, Tubita V, Piñeiro GJ, Revuelta I, Ventura-Aguiar P, Cucchiari D, Oppenheimer F, Brunet M, Campistol JM, Diekmann F .
    Referència: TRANSPLANTATION 2018; 102(7):1075-1084.
  • Pancreas outcomes between living and deceased kidney donor in pancreas after kidney transplantation patients.

    Autors: Ventura-Aguiar P, Ferrer J, Revuelta I, Paredes D, de Sousa-Amorim E, Rovira J, Esmatjes E, Garcia-Valdecasas JC, Campistol JM, Oppenheimer F, Diekmann F, Ricart MJ .
    Referència: NEPHROLOGY, DIALYSIS AND TRANSPLANTATION 2018; 33(11):2052-2059.
  • Pretransplant Use of Rituximab is Associated with Posttransplant Malignancies Events and Death by Neoplasia in Incompatibility Living Donor Kidney Transplants.

    Autors: Revuelta, I.; Tubita, V.; Cucchiari, D.; De Sousa, E.; Piselli, P.; Lozano, M.; Cid, J.; Palou, E.; Martorell, J.; Oppenheimer, F.; Diekmann, F.; Campistol, J.;.
    Referència: AMERICAN JOURNAL OF TRANSPLANTATION 2018.

Projectes destacats

  • Targeting endothelial dysfunction in highly prevalent diseases: characterization and validation of prognostic biomarkers and identification of potential therapeutic strategies

    Investigador/a principal: Josep M Campistol Plana
    Durada: 01/01/2016
  • ALN-TTR02-006 A multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisirian in Patients Amyloidotic Polyneuropathy who have completed a prior Clinical study with Patisiran

    Finançador: MEDPACE, INC
    Durada: 01/01/2015
  • ENSAYO PARA LA EVALUACION DE LA NEFROPROTECCION Y LA EFICACIA DE BELATACEPT COMO INMUNOSUPRESION EN PRIMERA LINEA - AMPLICACION DE CRITERIOS PARA DONANTES (BENEFIT-EXT)

    Finançador: QUINTILES, S.L
    Durada: 01/01/2015